ultomiris solución concentrada para solución para perfusión 300 mg/ 30 ml (ravulizumab)
astrazeneca s.a. - ravulizumab - sin formulas
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxística - inmunosupresores selectivos - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
ultomiris solución concentrada para solución para perfusion 300 mg / 3ml (ravulizumab)
astrazeneca s.a. - ravulizumab - sin formulas
ultomiris 300mg/3ml concentrado para solucion para perfusion
astrazeneca peru s.a. - droguerÍa - ravulizumab - concentrado para solucion para perfusion - 300 mg/3 ml - por vial 1.00 u - - ravulizumab
ultomiris 1100mg/11ml concentrado para solucion para perfusion
astrazeneca peru s.a. - droguerÍa - ravulizumab - concentrado para solucion para perfusion - 1100 mg/11 ml - por vial 11.00 ml - - ravulizumab
ultomiris solución concentrada para solución para perfusion 1100 mg/11 ml
astrazeneca s.a. - ravulizumab - sin formulas
ultomiris®
alexion pharmaceuticals inc estados unidos - cada ml contiene: ravulizumab??.100 mg/ml - concentrado para solución para perfusión - cada ml contiene: ravulizumab??.100 mg/ml
natalizumab elan pharma
elan pharma international ltd. - natalizumab - enfermedad de crohn - inmunoestimulantes, - el tratamiento de moderada a gravemente activa la enfermedad de crohn para la reducción de signos y síntomas, y la inducción y el mantenimiento de la respuesta sostenida y la remisión, en pacientes que no han respondido a pesar de un completo y adecuado curso de la terapia con corticosteroides e inmunosupresores; o que son intolerantes o tienen contraindicaciones médicas a dichas terapias.
lucentis solución inyectable 10 mg/ml (ranibizumab)
novartis chile s.a. - ranibizumab - ranibizumab 10 mg
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.